NCHR Testimony to FDA in Preparation for the 2017 International Cooperation on Cosmetics Regulation (ICCR) Meeting

May 25, 2017. In summary, endocrine disrupting chemicals and other harmful substances are present in many cosmetics in the United States. These substances can harm the health of adults and children, and it is essential for the FDA and the ICCR to consider the growing evidence for their harm. We urge the FDA and ICCR to establish high standards for maximum levels of endocrine disruptors and require manufacturers to clearly label their presence in products.

Read More »

NCHR Testimony to FDA About L-Glutamine for Sickle Cell Crisis

May 24, 2017. Sickle cell disease and the crises that it causes are a serious problem. Patients deserve and need new treatments. This requires high-quality clinical studies to demonstrate whether new treatments are effective and safe. When many of the patients that start a study drop out before it is completed, it is impossible to accurately evaluate the benefits compared to the risks. … FDA should approve new treatments based on clearly demonstrated evidence of efficacy and safety. This requires high-quality clinical trials where post patients stay in the trial. FDA should not approve a drug with questionable benefit when the dropout rate is concerning.

Read More »
Page 30 of 107« First...1020...2829303132...405060...Last »